At the beginning of the study, patients had an average FEV1 of about 64%.
FORBES: Vertex May Make History With Cystic Fibrosis Drug
That meant that the total FEV1 was about 17% higher in patients who received the drug.
The mean relative FEV1 across the combination dose groups returned toward baseline during the post-treatment 28-day washout period.
FORBES: Personalized Cystic Fibrosis Drugs Get A Booster Shot
The clinical trial would have been statistically significant if the 10.5 percentage point increase in FEV1 had been just 4.5 points.
In patients who took VX-770, this FEV1 value rose 10.5 percentage points.
应用推荐
模块上移
模块下移
不移动